ライフサイエンスコーパス: Toll-like receptor 9

1 ted to be a novel proinflammatory ligand for Toll-like receptor 9.

2 ly endocytic compartments in pDCs to trigger Toll-like receptor 9.

3 e Dectin-1/Card9 pathway and did not require toll-like receptor 9.

4 ferently directed to the B-cell receptor and Toll-like receptor 9.

5 recognition threshold for the activation of Toll-like receptor 9.

6 ction and organ damage through activation of Toll-like receptor 9.

7 s modified by the expression of its receptor toll-like receptor-9.

8 t was achieved, in part, by IFN-1 induced by Toll-like receptor 9-activated cDCs.

9 ort isoform predominates in CD27(+) B cells, toll-like receptor 9-activated peripheral B cells, and s

10 al NPs at the endosomal edge showed enhanced toll-like receptor 9 activation and secretion of proinfl

11 outcome of severe sepsis is associated with toll-like receptor 9 activation in neutrophils, which tr

12 cate lung-colonizing bacteria and inhibiting Toll-like receptor 9 activation to foster inflammation r

13 e bone marrow both in vitro and in vivo upon Toll-like receptor-9 activation and whose adoptive trans

14 Rationale: To examine the potential of TLR9 (Toll-like receptor 9) activation to modulate the type 2

15 Via Toll-like receptor 9 agonism of dendritic cells and B ce

16 Toll-like receptor-9 agonism with CYT003 showed no addit

17 ucleotide conjugated to a scavenger receptor/Toll-like receptor 9 agonist (C-miR146a).

18 treatment with antigen in the presence of a Toll-like receptor 9 agonist can suppress TH2-mediated r

19 ed either HIFU alone or were primed with the toll-like receptor 9 agonist CpG and the checkpoint modu

20 particle with CpG-motif G10 inside), a novel Toll-like receptor 9 agonist packaged into virus-like pa

21 A (siRNA) delivery platform by conjugating a Toll-like receptor 9 agonist with siRNA that efficiently

22 ed the IgG response by coadministration of a Toll-like receptor 9 agonist, among other adjuvants exam

23 wed that stimulation of innate immunity with Toll-like receptor 9 agonist, class B CpG (cytosine-phos

24 A toll-like receptor 9 agonist, CpG55.2, was also added as

25 imulation with a CpG oligodeoxynucleotide, a Toll-like receptor 9 agonist, evokes changes in the cent

26 missible gastroenteritis virus (TGEV) or the Toll-like receptor 9 agonist, oligodeoxynucleotide (ODN)

27 f CpG oligodeoxynucleotide 2216 (ODN2216), a Toll-like receptor 9 agonist, was investigated with mono

28 s formulated with the adjuvant PF03512676, a Toll-like receptor 9 agonist, which augments cellular im

29 Selectively targeting YTHDF2 in TAMs using a Toll-like receptor 9 agonist-conjugated small interferin

30 d ALDH antigen peptides together with CpG, a Toll-like receptor 9 agonist.

31 hout co-administration or encapsulation of a Toll-Like Receptor 9 agonist.

32 We found that in response to the Toll-like receptor-9 agonist CpGA, plasmacytoid dendriti

33 In a Phase 2a trial, CYT003, a Toll-like receptor-9 agonist immunomodulator, improved a

34 antigen peptides and CpG oligonucleotides (a Toll-like receptor-9 agonist).

35 hage colony-stimulating factor (GM-CSF), the Toll-like-receptor-9 agonist cytosine-guanosine oligodeo

36 We tested whether Toll-like receptor 9 agonists increased TACI expression

37 EV vaccines, we show that the conjugation of toll-like receptor 9 agonists onto EVs enables timely ac

38 otein formulated in Toll-like receptor 7 and Toll-like receptor 9 agonists, and DNA priming followed

39 naive B cells via B-cell receptor (BCR) and Toll-like receptor 9, along with T-cell help, failed to

40 Breg cells obtained by Toll-like receptor 9 and CD40 activation of B cells prev

41 naling influences the liver DC expression of toll-like receptor 9 and IL-1 receptor associated kinase

42 s for innate antiviral responses, triggering Toll-like receptor 9 and inducing alpha/beta interferon

43 Macrophage activation by CpG DNA requires toll-like receptor 9 and the adaptor protein MyD88.

44 id dendritic cells, leading to activation of Toll-like receptor-9 and induction of type I IFNs.

45 ral killer cell dependent and ineffective in Toll-like Receptor 9(-/-) and interleukin 6(-/-) mice, w

46 as partially CD4 dependent and functional in Toll-like Receptor 9(-/-) and interleukin 6(-/-) mice.

47 bacteria, T-cell-independent activation via Toll-like receptor 9, and differentiation into non-NTHi-

48 , Henault et al. show that Fcgamma-receptor, Toll-like receptor 9, and LC3 conspire to mold phagosome

49 phosphate-guanosine (CpG) DNA motifs through toll-like receptor 9, and we found that the synthetic Cp

50 somal acidification inhibitor chloroquine, a Toll-like receptor 9 antagonist inhibitory CpG DNA, or o

51 asmacytoid dendritic cells via activation of Toll-like receptor 9, but independently of the IL-26 rec

52 Upon investigating the mechanism by which toll-like receptor 9 deficiency prevents the failure of

53 Toll-like receptor 9-deficient mice with cecal ligation

54 cecal ligation and puncture in wild-type and toll-like receptor 9-deficient mice.

55 , it was found that neutrophils derived from toll-like receptor 9--deficient mice with cecal ligation

56 o a CpG oligodeoxynucleotide (ODN) targeting Toll-like receptor-9-expressing B cell lymphoma cells.

57 Neutrophil Toll-like receptor 9 expression correlated with plasma i

58 These data point to neutrophil Toll-like receptor 9 expression in acetaminophen-induced

59 Healthy neutrophil Toll-like receptor 9 expression increased upon stimulati

60 Circulating neutrophil Toll-like receptor 9 expression was increased in acetami

61 e score (2-4) on day 1 had higher neutrophil Toll-like receptor 9 expression, arterial ammonia concen

62 sociated with mortality in patients with low toll-like receptor-9 expression (odds ratio, 1.1; p = 0.

63 Stratification of patients according to toll-like receptor-9 expression above/below median demon

64 Toll-like receptor-9 expression in monocytes was measure

65 particular present in patients with elevated toll-like receptor-9 expression.

66 e liver failure plasma and endogenous DNA on Toll-like receptors-9 expression, healthy neutrophils we

67 he toll-like receptor 4 gene (TLR4), and the toll-like receptor 9 gene (TLR9) in a cohort of 336 reci

68 ivo or in vitro activation within the BM via Toll-like receptor-9 generates a population of plasmacyt

69 Unexpectedly, loss of the Toll-like receptor 9 has a minimal effect on Akt activat

70 cognize CpG DNA express membrane-bound human Toll-like receptor 9 (hTLR9).

71 -kappaB-->ZEB1 signaling represses the TLR9 (toll-like receptor 9), IFNG, MCP-1 (monocyte chemoattrac

72 Colocalization of CpG DNA with Toll-like receptor 9 in endosomal vesicles is disrupted

73 transfer of invasive behavior by activating Toll-like receptor 9 in recipient cells, and this involv

74 e of MTMR3 in IgAN pathogenesis by enhancing Toll Like Receptor 9-induced IgA immunity.

75 dence that Mtmr3-/- mice exhibited defective Toll Like Receptor 9-induced IgA production, glomerular

76 Toll-like receptor 9 with a telomere-derived Toll-like receptor 9 inhibitory oligonucleotide or trans

77 Our study identifies Toll-like receptor 9 inhibitory oligonucleotides as pote

78 or 9 inhibitory oligonucleotide or transient Toll-like receptor 9 knockdown with small interfering RN

79 and defective responses to stimulation with Toll-like receptor 9 ligand (TLR9-L), regardless of the

80 our previous finding that the combination of Toll-like receptor 9 ligand CpG and interleukin (IL)-4 s

81 rial DNA, a distinct class of interferogenic toll-like receptor 9 ligand(3).

82 or to treatment with poly-ICLC or a specific Toll-like receptor 9 ligand, CpG oligodeoxynucleotides.

83 toll-like receptor-9 ligand, CpG DNA, enhanced luciferas

84 or prostate cancer cells stably adorned with Toll-like receptor-9 ligand-loaded particles using strep

85 tion of IL-8 was observed using conventional Toll-like receptor 9 ligands (CpG oligonucleotides), alt

86 tory CD80/CD86 in the steady state and after Toll-like receptor 9 ligation.

87 After Toll-like receptor-9 ligation, expanded liver pDCs secre

88 adation after pressure overload can activate Toll-like receptor-9 mediated innate immunity, causing m

89 in CLL by suppressing BCR, CD49d, CD40, and Toll-like receptor 9-mediated AKT activation in an integ

90 In contrast to the Toll-like receptor 9-mediated recognition observed in pl

91 pite functionally intact IL-21 receptor- and Toll-like receptor 9-mediated signal transducer and acti

92 CD40 ligand- and Toll-like receptor 9-mediated signaling were less strong

93 eatment inhibited Toll-like receptor 4, MD2, Toll-like receptor 9, myeloid differentiation factor 88,

94 fs mimic microbial DNA and are recognized by toll-like receptor 9 on immune cells.

95 at stimulate innate immune responses through Toll-like receptor-9 on B cells and plasmacytoid dendrit

96 vates the innate immune system by binding to toll-like receptor-9 on immune cells.

97 e in vitro stimulation of B-cell receptor or Toll-like receptor 9 pathways were reduced in patients w

98 synthase-stimulator of interferon genes) and Toll-like receptor 9) preferentially in APCs by promotin

99 Lung ST2L and toll-like receptor 9 protein expression levels concomita

100 Toll-like receptor 9 recognizes CpG DNA and elicits inna

101 dings demonstrate that bacterial DNA through Toll-like receptor 9 shifted the balance of tissue facto

102 d that only patients with high expression of toll-like receptor-9 showed an increased risk associated

103 e reversed by activation of APCs via CD40 or Toll-like receptor 9 signaling.

104 l and that TRAF6 is a diverging point in the Toll-like receptor 9-signaling pathway for CpG DNA-media

105 h it could be demonstrated that parts of the Toll-like receptor 9-signaling pathway were functional,

106 se could be reduced or abolished by blocking toll-like receptor 9 signalling or by enzymatically redu

107 However, Toll-like receptor 9 stimulation alone significantly inc

108 recognition threshold for the activation of Toll-like receptor 9, the principal DNA-recognizing tran

109 erapy by cytosine-phosphate-guanine (CpG), a Toll-like receptor 9 (TLR-9) agonist combined with OX40

110 cterial DNA enhance immune responses through Toll-like receptor 9 (TLR-9) and may also demonstrate ad

111 ion in human monocytic cells (THP-1) through Toll-like receptor 9 (TLR-9) and nuclear factor-kappaB s

112 oduction by human PDCs through engagement of Toll-like receptor 9 (TLR-9) and TLR-7, respectively, wi

113 The Toll-like receptor 9 (TLR-9) gene has recently emerged a

114 rich in unmethylated CG motifs (CpGs) engage Toll-Like Receptor 9 (TLR-9) in endosomes and are well d

115 Toll-like receptor 9 (TLR-9) is a protein that helps our

116 er cells after vaccination with antigen plus Toll-like receptor 9 (TLR-9) ligand.

117 pression of bacterial DNA sensors, including Toll-like receptor 9 (TLR-9), DNA-dependent activator of

118 d CpG-containing DNA, which is recognized by Toll-like receptor 9 (TLR-9), has been strongly implicat

119 ization to early endosomes and signaling via Toll-like receptor 9 (TLR-9), it can result in product p

120 flammatory contributors to a murine model of Toll-like receptor 9 (TLR-9)-induced fulminant MAS.

121 , and the capacity to respond to ligands for Toll-like receptor 9 (TLR-9; CpG ODN 1668), but not to l

122 focuses on sublingual immunotherapy (SLIT), toll-like receptor-9 (TLR-9) vaccines using cytosine pho

123 To determine whether mast cells express Toll-like receptor-9 (TLR-9; the receptor for ISS), TLR-

124 Although the well-known Toll like receptor 9 (TLR9) agonist CpGODN has shown pro

125 ich was prevented by CXCR2-FPR1 blockage and Toll-like receptor 9 (TLR9) absence (TLR9(-/-) mice).

126 ulatory: LL37-DNA complexes potently amplify Toll-like receptor 9 (TLR9) activation in immune cells a

127 lites and peptidoglycan into host cells, and Toll-like receptor 9 (TLR9) activation is attributed to

128 g cellular uptake of CpG to generate greater toll-like receptor 9 (TLR9) activation than CpG alone.

129 ication (FLT3-ITD)-negative AML, BTK couples Toll-like receptor 9 (TLR9) activation to nuclear factor

130 h abnormal gene fusion, immune response, and Toll-like receptor 9 (TLR9) activation.

131 We did this by leveraging the fact that toll-like receptor 9 (TLR9) agonism within pools of huma

132 Similar effects were observed using a Toll-like receptor 9 (TLR9) agonist (oligonucleotide 239

133 re cultured with CD40 ligand (CD40L) and the Toll-like receptor 9 (TLR9) agonist cytidine-phosphate-g

134 Previous clinical studies suggest that the Toll-Like Receptor 9 (TLR9) agonist DIMS0150 not only in

135 lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic ant

136 pathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an a

137 a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and i

138 uanidine (CpG) oligodeoxynucleotide (ODN), a toll-like receptor 9 (TLR9) agonist, confers protection

139 thesized that a single drug molecule-a novel Toll-like receptor 9 (TLR9) agonist, MGN1703-could funct

140 dulates the type I IFN response of IPCs to a Toll-like receptor 9 (TLR9) agonist.

141 Toll-like receptor 9 (TLR9) agonists have gained tractio

142 Toll-like receptor 9 (TLR9) agonists such as unmethylate

143 his study we observed that administration of Toll-like receptor 9 (TLR9) agonists suppressed the seve

144 stry, we conjugated CpG oligodeoxynucleotide toll-like receptor 9 (TLR9) agonists to the pAMF sites o

145 lymphocyte-associated antigen 4 (CTLA4) and toll-like receptor 9 (TLR9) agonists.

146 ly, we identify parasite DNA-sensing through Toll-like receptor 9 (TLR9) along with inflammatory cyto

147 Unmethylated CpG DNA binds to the Toll-like receptor 9 (TLR9) and activates NF-kappaB to i

148 ells (RBCs) express the nucleic acid-binding toll-like receptor 9 (TLR9) and bind CpG-containing DNA.

149 obed two intracellular DNA sensing pathways, toll-like receptor 9 (TLR9) and cyclic GMP-AMP synthase

150 okines via a cooperative interaction between Toll-like receptor 9 (TLR9) and FcgammaRIIa (CD32).

151 Toll-like receptor 9 (TLR9) and NLRP3 inflammasome were

152 Toll-like receptor 9 (TLR9) and Phosphatidylinositol-3-k

153 nition of adenovirus by pDCs was mediated by Toll-like receptor 9 (TLR9) and was dependent on MyD88,

154 Furthermore, we showed that inhibition of Toll-like receptor 9 (TLR9) attenuates mtDNA-induced soc

155 70S6K1 and p70S6K2, during pDC activation by Toll-like receptor 9 (TLR9) blocked the interaction of T

156 Stimulation of Toll-like receptor 9 (TLR9) by DNA is important in the a

157 Toll-like receptor 9 (TLR9) can control cryptococcosis a

158 major role in intestinal homeostasis through Toll-like receptor 9 (TLR9) engagement.

159 more robustly than canonical pDCs following Toll-like receptor 9 (TLR9) engagement.

160 Toll-like receptor 9 (TLR9) enhances proinflammatory res

161 The activation of Toll-like receptor 9 (TLR9) expressed within B cells is

162 clude the BMAL1:CLOCK heterodimer regulating toll-like receptor 9 (TLR9) expression and repressing ex

163 Although Toll-like receptor 9 (TLR9) has been implicated in cytok

164 l early in clinical development, agonists of Toll-like receptor 9 (TLR9) have demonstrated potential

165 The role of Toll-like receptor 9 (TLR9) in antifungal responses in t

166 engagement of the B cell receptor (BCR) and Toll-like receptor 9 (TLR9) in response to DNA-containin

167 -mobility group B1 (HMGB1) protein activates Toll-like receptor 9 (TLR9) in the adipose-recruited pDC

168 a key role in recognition, as highlighted by Toll-like receptor 9 (TLR9) in the endosomal compartment

169 Toll-like receptor 9 (TLR9) is a pattern recognition rec

170 Toll-like receptor 9 (TLR9) is a promising candidate tha

171 Toll-like receptor 9 (TLR9) is a regulator of disease pa

172 The Toll-like receptor 9 (TLR9) is activated by DNA presente

173 Toll-like receptor 9 (TLR9) is an endosome bound, innate

174 At present, Toll-like receptor 9 (TLR9) is thought to play a central

175 that following challenge with A. fumigatus, Toll-like receptor 9 (TLR9) knockout mice survived longe

176 We investigated the ability of the Toll-like receptor 9 (TLR9) ligand CpG to modulate estab

177 ex comprised of a mast cell (MC) agonist and toll-like receptor 9 (TLR9) ligand to adjuvant a broadly

178 raft-versus-host disease (GVHD) lethality by Toll-like receptor 9 (TLR9) ligation of host antigen-pre

179 rse associated with fibroblast expression of Toll-Like Receptor 9 (TLR9) mediated by interactions wit

180 rse associated with fibroblast expression of Toll-like receptor 9 (TLR9) mediated by interactions wit

181 CLL cells selectively express high levels of Toll-like receptor 9 (TLR9) mRNA and proteins.

182 ecific pattern recognition receptors such as Toll-like receptor 9 (TLR9) on the endosomal surface of

183 A role for Toll-like receptor 9 (TLR9) recognition of Ad was suppor

184 Toll-like receptor 9 (TLR9) recognizes bacterial, viral

185 Toll-like receptor 9 (TLR9) recognizes genomes of double

186 Toll-like receptor 9 (TLR9) recognizes microbial DNA in

187 Toll-like receptor 9 (TLR9) recognizes unmethylated CpG

188 Toll-like receptor 9 (TLR9) senses microbial DNA and tri

189 d-induced IL-1beta release is dependent upon Toll-like receptor 9 (TLR9) sensing of the Ad5 double-st

190 endent on an autophagy and mitochondrial DNA/Toll-like receptor 9 (TLR9) signaling pathway.

191 ke into endosomes, the rate-limiting step of Toll-like receptor 9 (TLR9) signaling, is critical in el

192 to IgM-secreting plasma cells in response to Toll-like receptor 9 (TLR9) signaling.

193 responsiveness of paired lung fibroblasts to Toll-like receptor 9 (TLR9) stimulation by CpG-oligodeox

194 ab prior to IgE-FcepsilonRI crosslinking and Toll-like receptor 9 (TLR9) stimulation.

195 ning oligodeoxynucleotides (CpG ODNs) act on Toll-like receptor 9 (TLR9) that is expressed on B cells

196 induction of NK-cell activity in response to Toll-like receptor 9 (TLR9) triggering.

197 tion and immunoglobulin production driven by Toll-like receptor 9 (TLR9) were considerably lower in D

198 stimulated the innate immune system via the Toll-like receptor 9 (TLR9) with cytosine-guanosine-cont

199 act with ACs, results from the engagement of Toll-like receptor 9 (TLR9) within the B cell after reco

200 role for the innate immune-sensing molecule Toll-like receptor 9 (TLR9)(4), and its interaction with

201 Toll-like receptor 9 (TLR9), a member of the interleukin

202 hown that the genome of the vector activates Toll-like receptor 9 (TLR9), a pattern recognition recep

203 Toll-like receptor 9 (TLR9), a receptor for CpG DNA, has

204 h is recognized by the innate immunoreceptor Toll-like receptor 9 (TLR9), and acutely blocking TLR9 p

205 tic cells (pDCs), which sense AAV genomes by Toll-like receptor 9 (TLR9), and conventional DCs promot

206 ear factor-kappaB transcription factor RelB, toll-like receptor 9 (TLR9), and interferon consensus se

207 robial DNA to its cognate receptors, such as Toll-like receptor 9 (TLR9), can trigger inflammation.

208 hed oligodeoxynucleotide, an agonist for the toll-like receptor 9 (TLR9), induces the activation of n

209 Toll-like receptor 9 (TLR9), its adaptor MyD88, the down

210 recruitment domain [ASC], NLRP3, caspase-1), Toll-like receptor 9 (TLR9), or the purinergic receptor

211 tic DNA rich in CpG dinucleotides stimulates Toll-like receptor 9 (TLR9), whereas DNA lacking CpG eit

212 pDCs sense viral DNA via Toll-like receptor 9 (TLR9), which has to be cleaved fro

213 ell-receptor signaling induces the fusion of Toll-like receptor 9 (TLR9)-containing endosomes with in

214 Toll-like receptor 9 (TLR9)-deficient (TLR9(-/-)) mice a

215 ow that Opn deficiency substantially reduced Toll-like receptor 9 (TLR9)-dependent IFN-alpha response

216 Here, we report a novel Toll-like receptor 9 (TLR9)-dependent mechanism that ini

217 e and antibody production by B cells via the Toll-like receptor 9 (TLR9)-dependent pathway.

218 osis-induced apoptosis in human PMNs through Toll-like receptor 9 (TLR9)-mediated release of neutroph

219 FcvarepsilonRI receptor for IgE, followed by Toll-like receptor 9 (TLR9)-mediated sensing of DNA in p

220 intravenous DNASE1 injection or ablation of Toll-like receptor 9 (TLR9)-mediated sensing significant

221 227A signaling and B-cell receptor (BCR)- or Toll-like receptor 9 (TLR9)-mediated signaling was also

222 In this study, we report that the Toll-like receptor 9 (TLR9)-MyD88 pattern-recognition re

223 trategy based on targeted Stat3 silencing in Toll-like receptor 9 (TLR9)-positive hematopoietic cells

224 lock controls the expression and function of Toll-like receptor 9 (TLR9).

225 activates the innate immune response through Toll-like receptor 9 (TLR9).

226 ng unmethylated CpG motifs act as ligands of Toll-like receptor 9 (TLR9).

227 oligodeoxynucleotide (CpG), a ligand for the Toll-like receptor 9 (TLR9).

228 containing unmethylated CpG motifs activate Toll-like receptor 9 (TLR9).

229 og CpG-ODN activates innate immunity through Toll-like receptor 9 (TLR9).

230 cells is known to activate immune cells via Toll-like receptor 9 (TLR9).

231 immune responses generated through MyD88 and Toll-like receptor 9 (TLR9).

232 containing unmethylated CpG motifs activate Toll-Like Receptor 9 (TLR9).

233 taining oligodeoxynucleotides that stimulate toll-like receptor 9 (TLR9).

234 ning unmethylated CpG dinucleotides activate Toll-like receptor 9 (TLR9).

235 nflammatory response, presumably mediated by Toll-like receptor 9 (TLR9).

236 ctivate the vertebrate immune system through Toll-like receptor 9 (TLR9).

237 engagement of the B cell receptor (BCR) and Toll-like receptor 9 (TLR9).

238 rface expression of the nucleic acid-sensing Toll-like receptor 9 (TLR9).

239 acrophages following CIH exposure, including toll-like receptor 9 (TLR9).

240 a defective response to ligation of BCR and Toll-like receptor 9 (TLR9).

241 ession of the pathogen recognition receptor, Toll-like receptor 9 (TLR9).

242 NA and contributed to pattern recognition by Toll-like receptor 9 (TLR9).

243 pG-ODN), the microbial DNA mimetic sensed by toll-like receptor 9 (TLR9).

244 s type 1 (HSV-1) in vitro is mediated by the toll-like receptor 9 (TLR9)/MyD88 pathway.

245 Toll-like receptor-9 (TLR9) has been shown to sense bact

246 Toll-like receptor-9 (TLR9) is largely responsible for d

247 r advanced glycation end products (RAGE) and Toll-like receptor-9 (TLR9).

248 ndritic cells (pDCs) by binding to endosomal Toll-like receptor-9 (TLR9; refs 1-5).

249 Although Toll-like receptor 9 triggering normally up-regulates B-

250 stem and microglia/macrophage activation via Toll-like receptor 9 using CpG (cytosine-phosphate-guani

251 Intracellular Toll-like receptor 9 was induced by costimulation with i

252 th CRS, although a 50% reduced expression of Toll-like receptor 9 was reported in patients with recal

253 vivo stimulation of MZ B cells through TLR9 (Toll-like receptor 9), we observed increased interleukin

254 Inhibition of Toll-like receptor 9 with a telomere-derived Toll-like r

255 -containing oligodeoxynucleotides binding to toll-like receptor 9, with enhanced IFN-alpha transcript